Enliven Therapeutics, Inc. (ELVN) - Dilution Analysis

Visualizing historical and potential share dilution over time

View Stock Details

Chase Ink Business Preferred®

Earn Up to 150K Bonus Points

Transfer points to 14+ airline & hotel partners. Up to 40% upgrade value on first class travel. $95/yr.

Apply Now

Dilution Analysis

High Risk

Significant dilution risk

Last updated: May 07, 2026

Risk Assessment Details

Potential Dilution: 31.92% of current shares

Recent Dilution: 31.04% (2 years)

Historical Dilution Factor: significant recent dilution

Outstanding Shares

63M

Potential Supply

20M

Additional shares possible

Splits

None

Past 2 years

Summary

ELVN currently has 62.8M outstanding shares. with moderate dilution risk from 20M authorized shares representing 31.9% potential dilution. The company has significantly diluted shareholders by 31.04% over the past 2 years, indicating aggressive capital raising.

Share Structure Timeline

Outstanding Shares

Total Supply

Historical Data Points

Date	Event	Outstanding	Supply
May 07, 2026	10-Q filing \| 62.8M shares outstanding	63M	20M
Nov 12, 2025	10-Q filing \| 62.1M shares outstanding	62M	20M
Aug 13, 2025	10-Q filing \| 59.2M shares outstanding	59M	20M
May 14, 2025	10-Q filing \| 50.1M shares outstanding	50M	20M
Mar 13, 2025	10-K filing \| 47.1M shares outstanding	47M	20M
Nov 13, 2024	10-Q filing \| 48.3M shares outstanding	48M	20M
Aug 13, 2024	10-Q filing \| 48.1M shares outstanding	48M	20M
May 14, 2024	10-Q filing \| 47.0M shares outstanding	47M	20M
Apr 18, 2024	S-3 filing: This prospectus relates to the offer and resale from time to time of up to 6,428,649 shares of common stock by the selling stockholders.	41M	20M
Mar 14, 2024	10-K filing \| 41.3M shares outstanding	41M	14M
Nov 09, 2023	10-Q filing \| 41.0M shares outstanding	41M	14M
Aug 10, 2023	10-Q filing \| 41.0M shares outstanding	41M	14M
Jun 23, 2023	S-3 filing: The company intends to offer common stock, preferred stock, depositary shares, debt securities, warrants, subscription rights, purchase contracts and units in one or more offerings up to an aggregate amount of $400 million.	41M	14M
May 11, 2023	10-Q filing \| 41.1M shares outstanding	41M	14M
Feb 10, 2023	10-K filing \| 26.3M shares outstanding	26M	14M
Oct 25, 2022	10-Q filing \| 26.3M shares outstanding	26M	14M
Aug 03, 2022	10-Q filing \| 26.3M shares outstanding	26M	14M
May 06, 2022	10-Q filing \| 26.3M shares outstanding	26M	14M
Mar 15, 2022	10-K filing \| 26.3M shares outstanding	26M	14M
Nov 09, 2021	10-Q filing \| 26.3M shares outstanding	26M	14M
Aug 06, 2021	10-Q filing \| 26.2M shares outstanding	26M	14M
May 11, 2021	10-Q filing \| 17.6M shares outstanding	18M	14M
Apr 01, 2021	S-3 filing: The company may offer and sell securities from time to time in one or more offerings of up to $200,000,000 in aggregate offering price for general corporate purposes.	18M	14M
Mar 05, 2021	10-K filing \| 17.6M shares outstanding	18M	4.5M
Nov 05, 2020	10-Q filing \| 17.4M shares outstanding	17M	4.5M
Aug 14, 2020	10-Q filing \| 17.3M shares outstanding	17M	4.5M
May 07, 2020	10-Q filing \| 17.3M shares outstanding	17M	4.5M
Mar 10, 2020	S-1/A filing: The company is offering 4,450,000 shares of common stock with the aim of raising approximately $66.4 million, planning to utilize the net proceeds along with existing funds to advance its research and development programs and for general corporate purposes.	N/A	4.5M
Mar 03, 2020	S-1/A filing: This is an S-1/A filing for the registration of common stock with a proposed maximum aggregate offering price of $92,115,000.	N/A	5.4M

Back to ELVN Details